menu
    • menu
    [{"orgOrder":0,"company":"George Medicines","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Metformin","moa":"||NADH dehydrogenase","graph1":"Endocrinology","graph2":"Phase II","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"George Medicines \/ CUREator","highestDevelopmentStatusID":"8","companyTruncated":"George Medicines \/ CUREator"},{"orgOrder":0,"company":"George Medicines","sponsor":"Bausch Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Bausch Health"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"},{"orgOrder":0,"company":"George Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Telmisartan","moa":"||ACE receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"George Medicines","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"George Medicines \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"George Medicines \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by George Medicines

    Menu

    George Medicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Bausch Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            George Medicines, Bausch Health Sign Licensing Agreement for GMRx2 in Canada

                            Details : Under the terms of the licensing agreement, Bausch Health will hold the exclusive rights to commercialize, GMRx2 in Canada, Mexico etc. It is being evaluated for the treatment of hypertension.

                            Product Name : GMRx2

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 13, 2025

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bausch Health

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Files NDA with FDA for Triple Combination Therapy for Hypertension

                            Details : GMRx2 is a triple combination of telmisartan, amlodipine and indapamide, in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.

                            Product Name : GMRx2

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 08, 2024

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Completes Recruitment of First Phase III Hypertension Trial Investigating Novel Single-pill T...

                            Details : GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhag...

                            Product Name : GMRx2

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 07, 2023

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : CUREator

                            Deal Size : $1.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            George Medicines Advances Triple Combination Candidate GMRx4 Into Phase II Clinical Development for First-Line...

                            Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...

                            Product Name : GMRx4

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 20, 2022

                            Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : CUREator

                            Deal Size : $1.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Provides Single-pill Triple Combination Candidate for Hypertension to VERONICA-Nigeria trial

                            Details : GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.

                            Product Name : GMRx2

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 09, 2022

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed

                            George Medicines

                            United Kingdom arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            George Medicines Initiates Two Phase III Trials of Triple Combination Candidate to Treat Hypertension

                            Details : GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.

                            Product Name : GMRx2

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 07, 2021

                            Lead Product(s) : Telmisartan,Amlodipine,Indapamide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth